SEC Comment Letter 0000000000-23-008963 to CERENOME, INC. (PSTV)
CERENOME, INC.
Date: Aug. 16, 2023 · CIK: 0001095981 · Accession: 0000000000-23-008963
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273823
Letter
United States securities and exchange commission logo August 16, 2023 Andrew Sims Chief Financial Officer Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 Re:Plus Therapeutics, Inc. Registration Statement on Form S-1 Filed August 9, 2023 File No. 333-273823 Dear Andrew Sims: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: William Intner
Show Raw Text
United States securities and exchange commission logo
August 16, 2023
Andrew Sims
Chief Financial Officer
Plus Therapeutics, Inc.
4200 Marathon Blvd., Suite 200
Austin, TX 78756
Re:Plus Therapeutics, Inc.
Registration Statement on Form S-1
Filed August 9, 2023
File No. 333-273823
Dear Andrew Sims:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: William Intner